Approval · Notice of Compliance 4637 · 1996
ULTIVA: Notice of Compliance 4637
Issued December 24, 1996
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4637
- Date
- December 24, 1996
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Opioid component to anaesthesia
Products in this notice
Medicinal ingredients
- REMIFENTANIL HCL 1 MG per VIAL
- REMIFENTANIL HCL 2 MG per VIAL
- REMIFENTANIL HCL 5 MG per VIAL